Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
Published: 14:04 08 Oct 2026 BST
Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a shareholder update marking its third anniversary.
The Nasdaq-listed biotech said its priorities are to advance selected clinical and regulatory milestones, align organizational costs with those priorities, and pursue licensing and co-development opportunities.
Partnerships could contribute non-dilutive funding and expertise while reducing the capital Medicus would otherwise need to provide, though timing and terms remain uncertain.
The portfolio is anchored by CD228V, an investigational antibody-drug conjugate that uses Pfizer's established vedotin linker-payload platform. Medicus plans to focus first on melanoma, particularly relapsed, refractory or immunotherapy-resistant disease, and to integrate biomarker work to better understand which patients may benefit.
The company also sees potential in CD228-expressing lung, head and neck, and esophageal cancers.
For SkinJect, the US Food and Drug Administration has authorized initiation of SKNJCT-005, a planned registrational study in patients with Gorlin syndrome, a rare autosomal dominant disease. The study follows completion of the Phase 2 SKNJCT-003 trial, which identified the 200-microgram dose for further development.
In urology and women's health, Medicus is advancing Teverelix, a next-generation GnRH antagonist acquired through Antev in August 2025. Priorities include acute urinary retention relapse prevention and symptomatic endometriosis, alongside a partnership-led strategy in advanced prostate cancer.
The company recently submitted an optimized registrational protocol for that indication, designed to give potential partners a clearer development plan, subject to FDA review.
Medicus said it has raised approximately $90 million through equity and debt financing since its start, supporting clinical development, acquisitions and operations while retaining resources for ongoing needs.